Investigation of SEN Virus Infection in Patients with Cryptogenic Acute Liver Failure, Hepatitis‐Associated Aplastic Anemia, or Acute and Chronic Non–A–E Hepatitis

Shinshu University, Shonai, Nagano, Japan
The Journal of Infectious Diseases (Impact Factor: 6). 12/2003; 188(10):1545-52. DOI: 10.1086/379216
Source: PubMed


SEN virus (SENV) has been tentatively linked to transfusion-associated non-A-E hepatitis. We investigated SENV's role in unexplained hepatitis in other settings. Polymerase chain reaction amplification was used to detect 2 SENV variants (SENV-D and SENV-H) in 1706 patients and control subjects. SENV was detected in 54 (22%) of 248 patients with acute or chronic non-A-E hepatitis, 9 (35%) of 26 patients with hepatitis-associated aplastic anemia, and 0 of 17 patients with cryptogenic acute liver failure, compared with 150 (24%) of 621 control subjects with liver disease and 76 (10%) of 794 healthy control subjects. When controlling for geographic region, the prevalence of SENV among case and control subjects was not significantly different. The severity of acute or chronic hepatitis A, B, or C was not influenced by coexisting SENV infection. No etiological role for SENV in the cause of cryptogenic hepatitis could be demonstrated.

2 Reads
  • Source
    • "Anti-nuclear antibody (ANA) and anti-smooth muscle antibody (SMA) were determined as reported previously.[20] Liver cirrhosis was diagnosed by histological examination and/or characteristic clinical signs of advanced liver disease.[21] HCC was diagnosed by histological examination and/or imaging studies, and hepatic failure was diagnosed by the presence of esophageal varices, ascites, and hepatic encephalopathy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although we earlier demonstrated that the human leukocyte antigen (HLA) DRB1*04:05 allele was associated with susceptibility to autoimmune hepatitis (AIH) in Japan, the precise relationship of HLA haplotype and the role of amino acid alignment with disease susceptibility and progression has not been fully clarified. We reinvestigated HLA class I A, B, and C and HLA class II DRB1, DQB1, and DPB1 alleles and haplotypes in a larger new cohort of 156 Japanese patients with type 1 AIH and compared them with the published data of 210 healthy subjects. The DRB1*04:05-DQB1*04:01 haplotype was significantly associated with AIH susceptibility (30% vs. 11%, P = 1.2×10-10; odds ratio [OR] = 3.51) and correlated with elevated serum IgG (3042 vs. 2606 mg/dL, P = 0.041) and anti-smooth muscle antigen positivity (77% vs. 34%, P = 0.000006). No associations with HLA-DPB1 alleles were found. The HLA A*24:02 and C*01:02 alleles were associated with disease susceptibility (corrected P = 0.0053 and 0.036, respectively), but this likely constituents of a long ranged haplotype including DRB1*04:05-DQB1*04:01 haplotype. Conversely, the DRB1*15:01-DQB1*06:02 haplotype was associated with protection from both disease onset (5% vs. 13%, P = 0.00057; OR = 0.38) and the development of hepatocellular carcinoma (25% vs. 5%, P = 0.017; OR = 6.81). The frequency of the DRB1*08:03-DQB1*06:01 haplotype was significantly higher in patients who developed hepatic failure (22% vs. 6%, P = 0.034; OR = 4.38). In conclusion, this study established the role of HLA haplotypes in determining AIH susceptibility and progression in the Japanese population. Additional sequencing of the entire HLA region is required to more precisely identify the genetic components of AIH.
    PLoS ONE 06/2014; 9(6):e100565. DOI:10.1371/journal.pone.0100565 · 3.23 Impact Factor
  • Source
    • "Overall the Korean population is estimated to be infected up to 5.1% by HBV and/or HCV, [Shin, 2006; Wong and Goh, 2006; Ministry of Health and Welfare, 2009]. HBV and HCV both can cause viremia [Umemura et al., 2003; Tassopoulos et al., 2008] and Vesivirus can also cause viremia [Smith et al., 2006]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A highly significant increase in anti-Vesivirus (family Caliciviridae) antibody prevalence, along the axis from healthy blood donors; donors with elevated transaminase; patients with clinical hepatitis; and patients with post-transfusion/dialysis hepatitis, has been reported in human sera from the USA and Europe. Asian samples have now been tested retrospectively using serology and enzyme immunoassay (EIA) with a Vesivirus partial-capsid antigen expressed as a fusion protein. Anti-vesiviral antibodies were measured by optical densities (OD(650) ) and compared in patients separated by age, gender and Groups A-F as follows: Control Group A, an Experimental Group B, which was divided further into Group C, patients with elevated enzymes (alanine transaminase (ALT), aspartate transaminase (AST), and γ-glutamyl transpeptidase (γ-GT); Group D, patients receiving transfused blood; Group E, patients with high enzyme levels after transfusion; and Group F, hepatitis B and C positive patients. Using multivariate logistic regression analyses, a significantly greater proportion of patients receiving transfusion(s), were positive for anti-Vesivirus antibody compared with non-transfused patients (P = 0.008; OR: 3.86, 95% CI: 1.43-10.43). Also, anti-Vesivirus antibody was significantly associated with elevated biochemical liver function tests: ALT ≥120 IU or AST ≥ 120 IU (P = 0.017; OR: 4.23, 95% CI: 1.30-13.80). In the blood transfusion group, anti-Vesivirus antibody was significantly correlated with high enzyme levels (ALT, P = 0.018; AST, P = 0.010; γ-GT, P = 0.020). These data provide serologic evidence of vesiviral transfusion-transmission-associated disease, which could include infection of any organ system where cytopathology resulted in high levels of either ALT or AST. J. Med. Virol. 84:1943-1952, 2012. © 2012 Wiley Periodicals, Inc.
    Journal of Medical Virology 12/2012; 84(12):1943-52. DOI:10.1002/jmv.23422 · 2.35 Impact Factor
  • [Show abstract] [Hide abstract]
    Der Internist 10/1998; 39(9):999-1000. DOI:10.1016/S0016-5085(98)70503-7 · 0.31 Impact Factor
Show more